Cadrenal Therapeutics has entered a partnership with Abbott for the tecarfarin anticoagulation and haemocompatibility with left ventricular assist devices (TECH-LVAD) trial.
With Abbott’s support, Cadrenal aims to plan and execute the trial, which assesses the safety and efficacy of oral vitamin K antagonist, tecarfarin, in individuals with LVADs, under the partnership and data sharing agreement terms.
Go deeper with GlobalData
The company will receive Abbott’s insights from recent HeartMate 3 trials, including its support in designing the study, site recognition, trial awareness, and “expertise” on the HeartMate 3 LVAD.
Cadrenal Therapeutics CEO Quang Pham said: “We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrolment efforts.
“Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3 LVAD, advancing our commitment to bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years.”
Abbott’s mechanical circulatory support device, HeartMate 3 LVAD, is tailored for individuals with advanced heart failure. The device is used for both short- and long-term support in these patients.
It features Full MagLev Flow technology in the pump, which is said to “maintain” blood handling for decreasing complications as well as adverse events related to hemocompatibility.
Cadrenal is focused on developing tecarfarin to offer a “safer” anticoagulant alternative to warfarin for individuals with cardiac devices.
Tecarfarin has gained orphan drug designation for advanced heart failure individuals who are implanted with LVADs, and fast track status for those with end-stage kidney disease and atrial fibrillation.
